Syneos Health Expands Catalyst Site Program to Mainland China
Signs Agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
MORRISVILLE, N.C. – August 23, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (“Wuhan Union Hospital”). This agreement expands the Company’s clinical trial capabilities across a broader range of therapeutic areas in China.
Wuhan Union Hospital now joins the Syneos Health Catalyst Site Program, introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery. Together, Syneos Health and Wuhan Union Hospital aim to expedite study timelines, and enable sites, sponsors and patients to be more engaged throughout the entire clinical trial process.
“Our venture with Wuhan Union Hospital is part of Syneos Health’s global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “Wuhan Union Hospital is a first-class site in China. We believe this strategic collaboration will foster a stronger development of our clinical business in Central China and enhance benefits for the patients we serve in this region.”
Ma Ming, Director of Scientific Research Department, Wuhan Union Hospital said: “As a large site in Central China, Wuhan Union Hospital has been actively cooperating with all parties with an open attitude to promote the development of the clinical trial business. Our work with Syneos Health accelerates the development of future projects and lays the foundation for strategic cooperation in other areas. We look forward to further outstanding development from both parties.”
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Syneos Investor Relations Contact:
Senior Vice President, Investor Relations
+1 919 745 2745
Syneos Press/Media Contact:
Executive Director, External Communications
+1 908 763 3428